文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗成人起病毛发红糠疹:一项单臂临床试验及转录组分析

Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
PubMed 文献 · Br J Dermatol · 2022-07-15

这项开放标签单臂临床试验纳入12例毛发红糠疹患者,接受24周司库奇尤单抗治疗,主要终点为第28周PASI 75。11例可评估患者中6例(55%)达PASI 75、3例(27%)达PASI 90,PGA与DLQI显著改善,未发生严重治疗相关不良事件;转录组分析显示治疗可逆转皮损与非皮损皮肤转录差异,无应答者固有免疫通路过度活跃可能驱动耐药。

要点

  • 司库奇尤单抗治疗毛发红糠疹第28周PASI 75达55%(6/11)、PASI 90达27%(3/11)。
  • PGA(P=0.008)与DLQI(P=0.010)评分较基线显著改善。
  • 未发生严重治疗相关不良事件;无应答者固有免疫通路过度活跃可能参与耐药。

核心结论

  • 司库奇尤单抗似乎对毛发红糠疹有效,值得进一步研究。
  • 毛发红糠疹是具有转录异质性的疾病,这反映在其对治疗的反应差异上。
  • 作者认为,未来临床试验应考虑靶向其他IL-17亚型及固有免疫介质的药物。

研究设计与样本

  • 开放标签、单臂临床试验,招募12例毛发红糠疹患者,接受24周司库奇尤单抗治疗。
  • 主要终点为从基线至第28周银屑病面积和严重程度指数较基线改善≥75%(PASI 75)。
  • 次要终点包括PASI 90、医生总体评估(PGA)变化及皮肤病生活质量指数(DLQI)变化。
  • 对基线和第2周获取的皮损与非皮损皮肤活检进行RNA测序,比较样本组以识别差异基因表达和通路富集。
  • 该试验在ClinicalTrials.gov注册,注册号为NCT03342573。

主要发现

  • 第28周时,11例可评估患者中6例(55%)达到PASI 75,3例(27%)达到PASI 90。
  • PGA评分(P=0.008)和DLQI评分(P=0.010)随治疗显著改善。
  • 未遇到严重治疗相关不良事件。
  • 司库奇尤单抗治疗使皮损与非皮损皮肤之间的转录差异正常化。
  • 来自无应答患者的转录组数据提示,固有免疫通路过度活跃可能驱动对司库奇尤单抗的耐药。

关键数值与推荐

  • 主要终点PASI 75:第28周6/11例(55%)达到。
  • 次要终点PASI 90:第28周3/11例(27%)达到。
  • PGA评分改善P=0.008;DLQI评分改善P=0.010。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出司库奇尤单抗治疗毛发红糠疹似乎有效,但值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but interleukin (IL)-17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat PRP. We conducted an open-label, single-arm clinical trial of secukinumab, a monoclonal antibody that inhibits IL-17A, for the treatment of PRP. OBJECTIVES: To evaluate the clinical efficacy of secukinumab and define the transcriptomic landscape of PRP and its response to IL-17A blockade. METHODS: Twelve patients with PRP were recruited for an open-label trial of secukinumab. Patients received a 24-week course of secukinumab. The primary endpoint was a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) from baseline to week 28. Secondary endpoints included PASI 90, change in Physician's Global Assessment (PGA), and change in Dermatology Life Quality Index (DLQI). RNA sequencing was performed on lesional and nonlesional skin biopsies obtained at baseline and week 2. Sample groups were compared to identify differential gene expression and pathway enrichment. This trial was registered with ClinicalTrials.gov: 'Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris' - NCT03342573. RESULTS: At week 28, six of 11 patients (55%) achieved PASI 75, and three patients (27%) achieved PASI 90. PGA (P = 0.008) and DLQI scores (P = 0.010) showed significant improvement with treatment. No serious treatment-related adverse events were encountered. Treatment with secukinumab normalized transcriptional differences between lesional and nonlesional skin. Transcriptomic data from nonresponsive patients suggest that overactivity of innate immune pathways may be driving resistance to secukinumab. CONCLUSIONS: Secukinumab appears to be an effective treatment for PRP and warrants further investigation. PRP is a transcriptionally heterogeneous disease, reflecting its variable response to therapy. Agents targeting other IL-17 isoforms and innate immune mediators should be considered for future clinical trials. What is already known about this topic? The pathogenesis of pityriasis rubra pilaris is incompletely understood. Successful treatment has been reported with a variety of immunomodulatory agents, but disease is often refractory to therapy. Interleukin (IL)-17 is thought to drive keratinocyte proliferation and vascular dysfunction in this disease. A previous trial demonstrated efficacy of the anti-IL-17A drug ixekizumab for pityriasis rubra pilaris. What does this study add? Herein we describe the findings of a clinical trial of secukinumab, an anti-IL-17A monoclonal antibody, for the treatment of pityriasis rubra pilaris. Secukinumab was effective in treating pityriasis rubra pilaris. Our transcriptomic data give new insight into the expressional changes that occur in response to secukinumab and suggest mechanisms of treatment resistance.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022. PMID: 35701384. doi:10.1111/bjd.21708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。